ArticlemAbs2026
Near pan-alphavirus neutralization by an antibody-nanobody bispecific.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Alphaviruses represent a global concern, with some such as chikungunya virus currently infecting thousands in China and others such as Venezuelan equine encephalitis virus inducing neurological symptoms in 4-14% of infected individuals. A single antibody capable of protecting from all human-infecting alphaviruses, by achieving sufficient potency against each virus individually, may have high utility, as only a single therapeutic would then need to be stockpiled against this entire class of emerging pathogens. We previously identified an antibody, SKT05, with broad encephalitic alphavirus recognition, and we also identified nanobodies capable of neutralizing both arthritogenic and encephalitic alphaviruses. Here, we employ structure-based design to engineer a SKT05-nanobody bispecific, which has near pan-neutralization of alphaviruses that infect humans. Twenty-three designed SKT05-nanobody bispecifics broadly neutralized pseudotyped viruses expressing envelope proteins of encephalitic alphaviruses. With 10 of these bispecifics, we further assessed live arthritogenic alphavirus neutralization for Mayaro, O'nyong'nyong, Ross River, and Una viruses, observing potent neutralization for all of them with four bispecifics. The best of these four, V2C3-30-SKT05H, comprising the V2C3 nanobody genetically fused through a 30-amino acid linker to the heavy chain of SKT05, potently neutralized 9 of 11 tested alphaviruses that were phylogenetically proximal to all 26 alphaviruses that infect and cause symptoms in humans. Further, therapeutic administration of V2C3-30-SKT05H reduced viral loads in chikungunya virus-infected mice. Electron microscopy revealed that V2C3-30-SKT05H induced disorder of E1E2 spikes on the viral surface, suggesting E1E2 disassembly as a potential neutralization mechanism. Collectively, these results demonstrate near pan-neutralization of human-infecting alphaviruses by an antibody-nanobody bispecific.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.